What happened
Shares of Vir Biotechnology(NASDAQ: VIR) were down more than 44% as of 10:45 a.m. on Thursday after the company announced phase 2 trial results for an influenza A therapy candidate. The stock is down more than 49% so far this year.
So what
Vir focuses on immunology therapies to treat infectious diseases. Its only marketed product, Sotrovimab, is an early treatment for COVID-19 that it collaborated with GSK on, but sales of that therapy have been declining.
In a release before the markets opened on Thursday, Vir said that VIR-2482 failed to meet primary or secondary efficacy endpoints as a therapy to treat influenza A illness in a phase 2 trial. The therapy was given to roughly 3,000 participants and the company said among those who received the highest dose of VIR-2482 (1,200 milligrams), a non-statistically significant reduction of approximately 16% in influenza A illness was found.
The biotech has a good-sized pipeline, but making the trial failure more disappointing is that VIR-2842 is its only wholly owned candidate. Its other 10 pipeline programs are all part of collaborations with Alnylam Pharmaceuticals, Gilead Sciences, GSK, Brii Biosciences, or the Bill & Melinda Gates Foundation.
Now what
The setback is a big deal, but Vir does have several other therapies in phase 2 trials. The company said it expects readouts for its hepatitis B and hepatitis D programs later this year. In both programs, the company is testing monoclonal antibodies VIR-2218 and VIR-3434, sometimes in combination.
In the first quarter, Vir reported it had $63 million in revenue, down 96.2% year over year. It also said it lost $1.06 in earnings per share (EPS), compared to positive EPS of $3.93 in the same period last year. In Thursday's announcement, the company said it had $1.9 billion in cash, enough at its current burn rate to probably last into 2027.
10 stocks we like better than Vir Biotechnology
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Vir Biotechnology wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of July 17, 2023
Jim Halley has positions in GSK. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals and Gilead Sciences. The Motley Fool recommends GSK. The Motley Fool has a disclosure policy.
